Fingolimod for multiple sclerosis : mechanism of action, clinical outcomes, and future directions

Mehling, M. and Kappos, L. and Derfuss, T.. (2011) Fingolimod for multiple sclerosis : mechanism of action, clinical outcomes, and future directions. Current neurology and neuroscience reports, Vol. 11, H. 5. pp. 492-497.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6338639

Downloads: Statistics Overview


The oral sphingosine 1-phosphate receptor (S1PR) modulator fingolimod functionally antagonizes S1PR hereby blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. This results in a reduction in peripheral lymphocyte counts, including potentially encephalitogenic T cells. In patients with relapsing multiple sclerosis fingolimod has been shown to be an effective treatment. In phase 2 and phase 3 studies fingolimod-treated patients had reduced disease activity clinically and in MRI. Although severe infectious complications occurred in single cases treated with fingolimod, the frequency of overall infections was comparable in fingolimod-treated patients and controls. Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Clinical Neuroimmunology (Derfuss/Lindberg)
UniBasel Contributors:Derfuss, Tobias Johannes and Kappos, Ludwig and Mehling, Matthias
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Current Science
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:10 Apr 2015 09:13
Deposited On:10 Apr 2015 09:13

Repository Staff Only: item control page